COVID-19 Therapeutics

New and Notable: COVID-19 Therapeutics Announcements

May 17, 2022: FACT SHEET: Update on COVID-19 Therapeutics Distribution
May 12, 2022: FDA Authorizes Shelf-Life Extension for Sotrovimab From 12 to 18 Months
May 4, 2022: FDA Authorizes Shelf-Life Extension for Bamlanivimab From 18 to 24 Months
April 14, 2022: New Paxlovid Dose Pack Authorized by FDA
April 13, 2022: Statement Regarding Shelf-Life Extension of Bamlanivimab and Etesevimab
April 5, 2022: Distribution of Sotrovimab Paused to All HHS Regions

COVID-19 therapeutics can be used to prevent or treat eligible non-hospitalized patients who have tested positive for COVID-19 and have mild to moderate symptoms. Prevention and early treatment for eligible patients can help improve patient outcomes, reduce stress on healthcare facilities, and even save lives.

HHS/ASPR has purchased supplies of COVID-19 therapeutic products and we are working with state and territorial health departments as well as national healthcare and medical organizations and associations to get the treatments into the hands of healthcare providers quickly, with a focus on areas of the country hardest hit by the pandemic.